AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15864805 — intervention group
Group type: COMPARATOR
Intervention: Nonradioactive seeds (n = 60)
Number of subjects: 120
Study 14581404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense and prolonged exercise
Number of subjects: 20
Study 11026883 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and choice group
Number of subjects: 2107
Study 11026883 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control) group
Number of subjects: 2107
Study 11026883 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and choice group (infected women)
Number of subjects: 2107
Study 11026883 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control) group (infected women)
Number of subjects: 2107
Study 8860277 — intervention group
Group type: EXPERIMENTAL
Intervention: Community participation (Trial 1)
Number of subjects: 8
Study 8860277 — intervention group
Group type: EXPERIMENTAL
Intervention: Family physician involvement (Trial 2)
Number of subjects: 8
Study 8860277 — intervention group
Group type: COMPARATOR
Intervention: Community participation (Trial 2)
Number of subjects: 8
Study 1704837 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 36
Study 1704837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6510013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg) taken before food
Number of subjects: 663
Study 6510013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg) taken after food
Number of subjects: 663
Study 28810385 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise recommendation
Number of subjects: 49
Study 28810385 — intervention group
Group type: COMPARATOR
Intervention: Specific exercise recommendation
Number of subjects: 49
Study 28810385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 29730838 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium vapoenucleation
Number of subjects: 94
Study 29730838 — intervention group
Group type: COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Number of subjects: 94
Study 27191689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-PLD (bortezomib plus pegylated liposomal doxorubicin 30 mg/m² intravenously on day 4)
Number of subjects: 646
Study 27191689 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib alone (1.3 mg/m² intravenously on days 1, 4, 8, and 11 of every 21-day cycle)
Number of subjects: 646
Study 24803644 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group (n=11) received nine 30 minutes upper extremity VR therapy in standing plus conventional therapy
Number of subjects: 23
Study 24803644 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12) received only conventional therapy
Number of subjects: 23
Study 22695205 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐FNA with a stylet
Number of subjects: 100
Study 22695205 — intervention group
Group type: COMPARATOR
Intervention: EUS‐FNA without a stylet
Number of subjects: 100
Study 20827179 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive recognition of diastolic dysfunction during stress testing
Number of subjects: 0
Study 20827179 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of diastolic dysfunction
Number of subjects: 0
Study 18602155 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic background noise
Number of subjects: 0
Study 18602155 — intervention group
Group type: EXPERIMENTAL
Intervention: Babble background noise
Number of subjects: 0
Study 18602155 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 0
Study 16091787 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 18
Study 16091787 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18
Study 16091787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12614450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg once daily
Number of subjects: 611
Study 12614450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study 10741815 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 0
Study 10741815 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS-11)
Number of subjects: 0
Study 10741815 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Rating Scale (VRS-4)
Number of subjects: 0
Study 8637302 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program
Number of subjects: 0
Study 8637302 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator use
Number of subjects: 0
Study 1300205 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose, combination-drug clinical trial
Number of subjects: 0
Study 1300205 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory procedure based on RSM modeling
Number of subjects: 0
Study 3970796 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestion group (patients exposed to statements about touching their ear)
Number of subjects: 33
Study 3970796 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestion group
Number of subjects: 33
Study 3970796 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 30031593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling temperature of 18 °C
Number of subjects: 36
Study 30031593 — intervention group
Group type: COMPARATOR
Intervention: Cooling temperature of 22 °C
Number of subjects: 36
Study 26420821 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (10 sessions)
Number of subjects: 30
Study 26420821 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 30
Study 24612447 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to remain active
Number of subjects: 0
Study 24612447 — intervention group
Group type: COMPARATOR
Intervention: Advice to rest
Number of subjects: 0
Study 24612447 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy
Number of subjects: 0
Study 24612447 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy after a seven week waiting list
Number of subjects: 0
Study 22245235 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil based lipid emulsion (Intralipid®)
Number of subjects: 40
Study 22245235 — intervention group
Group type: COMPARATOR
Intervention: Olive oil based lipid emulsion (Clinoleic®)
Number of subjects: 40
Study 20968113 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyphenol chocolate (45 g daily for 8 weeks)
Number of subjects: 12
Study 20968113 — intervention group
Group type: COMPARATOR
Intervention: Low polyphenol chocolate (45 g daily for 8 weeks)
Number of subjects: 12
Study 18552464 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta therapy (6 MU daily for 6 or 8 weeks)
Number of subjects: 25
Study 15872029 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate retard 400 mg once daily
Number of subjects: 339
Study 15872029 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 339
Study 15872029 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 339
Study 15872029 — intervention group
Group type: EXPERIMENTAL
Intervention: triglycerides (50 mg/dL increment)
Number of subjects: 339
Study 15872029 — intervention group
Group type: EXPERIMENTAL
Intervention: fasting glucose (10 mg/dL increment)
Number of subjects: 339
Study 12431899 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracurricular activities intervention
Number of subjects: 3028
Study 12431899 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 3028
Study 12079015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine 150 mg + morphine 4 mg
Number of subjects: 60
Study 12079015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine 150 mg + morphine 4 mg + methylprednisolone 40 mg
Number of subjects: 60
Study 12079015 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular saline
Number of subjects: 60
Study 9785106 — intervention group
Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg once daily for 7 days
Number of subjects: 451
Study 9785106 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice daily for 7 days
Number of subjects: 451
Study 7696786 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous, warm, noncardioplegic retrograde blood perfusion (n = 37)
Number of subjects: 66
Study 7696786 — intervention group
Group type: COMPARATOR
Intervention: Antegrade perfusion
Number of subjects: 66
Study 2169701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoprotein
Number of subjects: 2
Study 2169701 — intervention group
Group type: COMPARATOR
Intervention: Control diet (meat)
Number of subjects: 2
Study 353682 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone sodium succinate intravenously, 30 mg/sq m every six hours (conventional dose)
Number of subjects: 21
Study 353682 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate intravenously, 300 mg/sq m every six hours (high dose)
Number of subjects: 21
Study 7168176 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg sulprostone administered intramurally into the cervix
Number of subjects: 154
Study 7168176 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 injections of 250 micrograms sulprostone administered intragluteally at 4 hour intervals
Number of subjects: 154
Study 29913227 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity light (9000 lx)
Number of subjects: 29
Study 29913227 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity light (<500 lx)
Number of subjects: 29
Study 29913227 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure
Number of subjects: 29
Study 26285057 — intervention group
Group type: EXPERIMENTAL
Intervention: MR perfusion studies
Number of subjects: 265
Study 26285057 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke jeopardy score
Number of subjects: 265
Study 26285057 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor image quality, triple-vessel disease, inadequate hemodynamic response
Number of subjects: 265
Study 24880345 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hemostat (COLL)
Number of subjects: 128
Study 24880345 — intervention group
Group type: COMPARATOR
Intervention: Carrier-bound fibrin sealant (CBFS)
Number of subjects: 128
Study 22983408 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal counseling based on Motivational Interviewing (MI) delivered during pregnancy and at well-baby visits.
Number of subjects: 272
Study 22983408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI-style counseling).
Number of subjects: 272
Study 22983408 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal counseling based on Motivational Interviewing (MI) with 4 or more sessions.
Number of subjects: 272
Study 20395129 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet chemotherapy
Number of subjects: 443
Study 20395129 — intervention group
Group type: COMPARATOR
Intervention: Standard doublet regimen
Number of subjects: 443
Study 20395129 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet chemotherapy in adenocarcinomas
Number of subjects: 443
Study 18356684 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine (160 mg valsartan plus amlodipine titrated from 2.5 to 10 mg)
Number of subjects: 296
Study 18356684 — intervention group
Group type: COMPARATOR
Intervention: Atenolol/Amlodipine (100 mg atenolol plus amlodipine titrated from 2.5 to 10 mg)
Number of subjects: 296
Study 18356684 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine
Number of subjects: 296
Study 18356684 — intervention group
Group type: COMPARATOR
Intervention: Atenolol/Amlodipine
Number of subjects: 296
Study 16275694 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication compliance
Number of subjects: 0
Study 16275694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium restrictions compliance
Number of subjects: 0
Study 12839658 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite-based intervention program at CISC
Number of subjects: 110000
Study 12839658 — intervention group
Group type: COMPARATOR
Intervention: Reference groups (control)
Number of subjects: 110000
Study 14530932 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 50 microg.kg(‐1) (maximum dose, 2.5 mg)
Number of subjects: 60
Study 14530932 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 8876342 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 . day‐1 x 5 g Cr.H2O + 2 g sucrose)
Number of subjects: 32
Study 8876342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 . day‐1 x 5 g Polycose + 2 g sucrose)
Number of subjects: 32
Study 1653913 — intervention group
Group type: EXPERIMENTAL
Intervention: Milacemide (glycine prodrug)
Number of subjects: 0
Study 1653913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6654627 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (3 X 0.66 mg)
Number of subjects: 136
Study 6654627 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine + Cyproheptadine (3 X 4 mg)
Number of subjects: 136
Study 6654627 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (3 X 100-3 X 50 mg)
Number of subjects: 136
Study 6654627 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine + Carbenoxolone
Number of subjects: 136
Study 6654627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 31717505 — intervention group
Group type: EXPERIMENTAL
Intervention: High SBP_Cv (≥11.9%)
Number of subjects: 835
Study 31717505 — intervention group
Group type: EXPERIMENTAL
Intervention: High DBP_Cv (≥22.4%)
Number of subjects: 835
Study 31717505 — intervention group
Group type: EXPERIMENTAL
Intervention: High MAP_Cv (≥13.6%)
Number of subjects: 835
Study 29205463 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous vaginal birth
Number of subjects: 880
Study 29205463 — intervention group
Group type: COMPARATOR
Intervention: Emergency repeat cesarean
Number of subjects: 880
Study 29205463 — intervention group
Group type: COMPARATOR
Intervention: Postnatal readmission of the mother
Number of subjects: 880
Study 29205463 — intervention group
Group type: COMPARATOR
Intervention: Public health insurance
Number of subjects: 880
Study 29205463 — intervention group
Group type: COMPARATOR
Intervention: Low antenatal HRQoL score
Number of subjects: 880
Study 26944891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 2 units of botulinum toxin type A (BTX‐A)
Number of subjects: 42
Study 26944891 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 4 units of botulinum toxin type A (BTX‐A)
Number of subjects: 42
Study 26944891 — intervention group
Group type: COMPARATOR
Intervention: Both dosages of BTX‐A (2 units and 4 units)
Number of subjects: 42
Study 25252807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy intervention (CBTi) for fear of falling
Number of subjects: 25
Study 22698066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg.kg(‐1) administered at 1‐2 post‐tetanic count (deep blockade)
Number of subjects: 131
Study 22698066 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 50 μg.kg(‐1) plus atropine 10 μg.kg(‐1) administered at the re‐appearance of the second twitch of a train‐of‐four stimulation (moderate blockade)
Number of subjects: 131
Study 20204689 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week group intervention designed to teach appropriate social behavior
Number of subjects: 44
Study 20204689 — intervention group
Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 44
Study 18607562 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional assist ventilation with load-adjustable gain factors (PAV+)
Number of subjects: 208
Study 18607562 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PS)
Number of subjects: 208
Study 16135188 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient (MMN) supplementation
Number of subjects: 499
Study 16135188 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 499
Study 16135188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499
Study 11798370 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA chelation therapy (40 mg/kg)
Number of subjects: 84
Study 11798370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 10472237 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms kg‐1
Number of subjects: 41
Study 10472237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8568042 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pass filtered white noise with cue tones at target frequencies (1000, 1259, 1585, and 2000 Hz) presented randomly on trials. Target frequency was the same as cue frequency on 60% of trials.
Number of subjects: 4
Study 8568042 — intervention group
Group type: COMPARATOR
Intervention: Fixed frequency tone condition where cue frequency always equaled target frequency and target was attenuated according to auditory filter attenuation at probe frequency.
Number of subjects: 4
Study 1912739 — intervention group
Group type: EXPERIMENTAL
Intervention: GUIDELINES
Number of subjects: 96
Study 1912739 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual
Number of subjects: 96
Study 1912739 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist
Number of subjects: 96
Study 1912739 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 96
Study 1912739 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes from baseline in GGT, MCV, and the Digit Symbol Test
Number of subjects: 96
Study 1912739 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist experience
Number of subjects: 96
Study 7094972 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin sulphate 1.5 g/d for 8 weeks
Number of subjects: 19
Study 7094972 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin sulphate 1.5 g/d and d‐thyroxine 6 mg/d for 8 weeks
Number of subjects: 19
Study 7094972 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin sulphate 1.5 g/d for up to 13 months
Number of subjects: 19
Study 7094972 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin sulphate 1.5 g/d for 4‐8 weeks
Number of subjects: 19
Study 7094972 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐thyroxine
Number of subjects: 19
Study 29769176 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding before, during, and after vaccination
Number of subjects: 48
Study 26446912 — intervention group
Group type: EXPERIMENTAL
Intervention: All-on-4
Number of subjects: 40
Study 26446912 — intervention group
Group type: EXPERIMENTAL
Intervention: All-on-6
Number of subjects: 40
Study 26446912 — intervention group
Group type: COMPARATOR
Intervention: All-on-4 and All-on-6
Number of subjects: 40
Study 25048848 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% 250 mg imiquimod ointment followed by intradermal TIV
Number of subjects: 91
Study 25048848 — intervention group
Group type: COMPARATOR
Intervention: Topical aqueous-cream followed by intramuscular TIV
Number of subjects: 91
Study 25048848 — intervention group
Group type: COMPARATOR
Intervention: Topical aqueous-cream followed by intradermal TIV
Number of subjects: 91
Study 22518940 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained participants
Number of subjects: 12
Study 22518940 — intervention group
Group type: COMPARATOR
Intervention: Untrained participants
Number of subjects: 12
Study 22518940 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained participants at 120 rpm
Number of subjects: 12
Study 22518940 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained participants at 90 rpm
Number of subjects: 12
Study 20688729 — intervention group
Group type: EXPERIMENTAL
Intervention: +2.00-D add over manifest correction
Number of subjects: 83
Study 20688729 — intervention group
Group type: COMPARATOR
Intervention: Single-vision lenses (SVLs)
Number of subjects: 83
Study 20688729 — intervention group
Group type: COMPARATOR
Intervention: Progressive addition lenses (PALs)
Number of subjects: 83
Study 18471387 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of contrast agent
Number of subjects: 63
Study 18471387 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mL of contrast agent
Number of subjects: 63
Study 18471387 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL of contrast agent
Number of subjects: 63
Study 18471387 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL of physiological serum at a rate of 4 ml/s
Number of subjects: 63
Study 15684301 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (15 beats/min faster than mean baseline nocturnal cardiac frequency) for 1 month
Number of subjects: 17
Study 15684301 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous rhythm for 1 month
Number of subjects: 17
Study 12915640 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 IU GH/m(2).d (approximately 0.033 mg/kg.d)
Number of subjects: 54
Study 12915640 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 IU GH/m(2).d (approximately 0.067 mg/kg.d)
Number of subjects: 54
Study 12915640 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-GH-treated)
Number of subjects: 54
Study 10555031 — intervention group
Group type: COMPARATOR
Intervention: Serum COMP levels in OA group (1,208.57 ± 487.47 ng/ml)
Number of subjects: 291
Study 10555031 — intervention group
Group type: COMPARATOR
Intervention: Serum COMP levels in age > or = 65 group (1,302.1 ± 496.7 ng/ml)
Number of subjects: 291
Study 10555031 — intervention group
Group type: COMPARATOR
Intervention: Serum COMP levels increase with knee OA K/L grade
Number of subjects: 291
Study 10555031 — intervention group
Group type: COMPARATOR
Intervention: Serum COMP levels increase with knee OA laterality
Number of subjects: 291
Study 10555031 — intervention group
Group type: COMPARATOR
Intervention: Serum COMP levels increase with number of knee and hip joints involved
Number of subjects: 291
Study 8947785 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (inhalation through the nose with stimuli delivered synchronously)
Number of subjects: 12